Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Next Previous
X
Search
Trial Profile

Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer; Carcinoma; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms AMBASSADOR; KEYNOTE-123

    • Most Recent Events

    • 27 Jan 2024 Results (n=702; Between 09/2017 and 08/2021) assessing the efficacy and safety of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma, presented at the 2024 Genitourinary Cancers Symposium.
    • 26 Jan 2024 According to a Merck & Co media release,trials other dual primary endpoint of overall survival did not reach statistical significance at the time of this interim analysis and will continue to be followed as data mature
    • 26 Jan 2024 According to a Merck & Co media release, result will be published in oral abstract session at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (abstract #LBA531).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top